The trial will involve both single and multiple-ascending doses of SUDO-550 being given to healthy volunteers.

D-2570 demonstrates robust efficacy and favorable safety profile, achieving skin clearance comparable to leading biologics - ...

Sudo Biosciences ("Sudo"), a biopharmaceutical company committed to designing and developing best-in-class precision TYK2 (tyrosine kinase 2) inhibitors, announced today that the first participants ...